In the present study, we investigated the effect in which HSP90 improves pulmonary arteriole remodeling, and explored the therapeutic utility of targeting HSP90 as therapeutic drug for PAH. This evidence concerns the gene HSP90AA1 and pulmonary arterial hypertension.